Inovio Q2 FY26 net loss narrows to $6.01 million; operating loss improves to $18.62 million
Reuters2026/08/12 20:09- Inovio posted a Q2 net loss of USD 6.01 million, narrowing from a USD 23.52 million loss a year earlier.
- R&D expense fell 25.41% to USD 10.83 million; G&A expense declined 8.9% to USD 7.8 million.
- Total operating expenses dropped 19.33% to USD 18.62 million, while operating loss narrowed to USD 18.62 million from USD 23.08 million.
- Cash, cash equivalents and short-term investments totaled USD 36.7 million at June 30, down from USD 58.5 million at Dec. 31.
- FDA review of the INO-3107 BLA advanced toward an Oct. 30, 2026 PDUFA date; cash runway guided into late Q1 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Oranjebtc cancels 25 million treasury shares without capital reduction
The Last Time Treasury Yields Hit 6%, Bitcoin Didn't Exist — What Happens If They Get There Again?
Crypto prices
More
